Breaking News

Financial Reports: Covance

By Gil Roth | February 5, 2014

Growth pushed by Late-Stage Development segment

Covance 4Q13

4Q Net Revenues: $623 million (+11%)

4Q Earnings: $36 million (+35%)

FY Net Revenues: $2.4 billion (+10%)

FY Earnings: $179 million (+89%)

Comments: Late-Stage Development revenues grew 15% in 4Q to $395 million, led by 17% growth in central laboratories and 13% growth in clinical development. FY revenues in Late-Stage Development were up 17% to $1.5 billion. Early Development revenues grew 5% in 4Q to $228 million, led by growth in clinical pharmacology and toxicology. For FY, Early Development revenues were flat at $871 million. The company cited discovery support and "certain pharmaceutical chemistry services" as areas of decline during the period.

Related Compliance:

blog comments powered by Disqus
  • CMO Systems

    CMO Systems

    Philip K. Burns, CRO Consulting||April 5, 2016
    A CMO system includes four aspects of the product lifecycle: regulatory, technical, compliance, and operations.

  • Injectables: The New Oral?

    Injectables: The New Oral?

    Tugrul Kararli, Kurt Sedo, Josef Bossart, PharmaCircle LLC||April 5, 2016
    The growth trend of injectables continues across the pharma landscape.

  • Biopharmaceutical Contract Manufacturing Contract Negotiations

    Biopharmaceutical Contract Manufacturing Contract Negotiations

    William Downey, HighTech Business Decisions||April 5, 2016
    Navigating the complexities of supply agreements.